Cargando…
Cost-effectiveness of human papillomavirus vaccine in China: a systematic review of modelling studies
OBJECTIVES: China suffers from high burdens of human papillomavirus (HPV) and cervical cancer, whereas the uptake of HPV vaccine remains low. The first Chinese domestic HPV vaccine was released in 2019. However, collective evidence on cost-effectiveness of HPV vaccination in China has yet to be esta...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8655525/ https://www.ncbi.nlm.nih.gov/pubmed/34880019 http://dx.doi.org/10.1136/bmjopen-2021-052682 |
_version_ | 1784612093047078912 |
---|---|
author | Shi, Wenchuan Cheng, Xiaoli Wang, Haitao Zang, Xiao Chen, Tingting |
author_facet | Shi, Wenchuan Cheng, Xiaoli Wang, Haitao Zang, Xiao Chen, Tingting |
author_sort | Shi, Wenchuan |
collection | PubMed |
description | OBJECTIVES: China suffers from high burdens of human papillomavirus (HPV) and cervical cancer, whereas the uptake of HPV vaccine remains low. The first Chinese domestic HPV vaccine was released in 2019. However, collective evidence on cost-effectiveness of HPV vaccination in China has yet to be established. We summarised evidence on the cost-effectiveness of HPV vaccine in China. DESIGN: Systematic review and narrative synthesis DATA SOURCES: PubMed, EMBASE, China National Knowledge Infrastructure and Wanfang Data were searched through 2 January 2021 ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Cost-effectiveness studies using a modelling approach focusing on HPV vaccination interventions in the setting of China were included for review. DATA EXTRACTION AND SYNTHESIS: We extracted information from the selected studies focusing on cost-effectiveness results of various vaccination programmes, key contextual and methodological factors influencing cost-effectiveness estimates and an assessment of study quality. RESULTS: A total of 14 studies were included for review. Considerable heterogeneity was found in terms of the methodologies used, HPV vaccination strategies evaluated and study quality. The reviewed studies generally supported the cost-effectiveness of HPV vaccine in China, although some reached alternative conclusions, particularly when assessed incremental to cervical cancer screening. Cost of vaccination was consistently identified as a key determinant for the cost-effectiveness of HPV vaccination programmes. CONCLUSIONS: Implementing HPV vaccination programmes should be complemented with expanded cervical cancer screening, while the release of lower-priced domestic vaccine offers more promising potential for initiating public HPV vaccination programmes. Findings of this study contributes important evidence for policies for cervical cancer prevention in China and methodological implications for future modelling efforts. |
format | Online Article Text |
id | pubmed-8655525 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-86555252021-12-27 Cost-effectiveness of human papillomavirus vaccine in China: a systematic review of modelling studies Shi, Wenchuan Cheng, Xiaoli Wang, Haitao Zang, Xiao Chen, Tingting BMJ Open Health Economics OBJECTIVES: China suffers from high burdens of human papillomavirus (HPV) and cervical cancer, whereas the uptake of HPV vaccine remains low. The first Chinese domestic HPV vaccine was released in 2019. However, collective evidence on cost-effectiveness of HPV vaccination in China has yet to be established. We summarised evidence on the cost-effectiveness of HPV vaccine in China. DESIGN: Systematic review and narrative synthesis DATA SOURCES: PubMed, EMBASE, China National Knowledge Infrastructure and Wanfang Data were searched through 2 January 2021 ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Cost-effectiveness studies using a modelling approach focusing on HPV vaccination interventions in the setting of China were included for review. DATA EXTRACTION AND SYNTHESIS: We extracted information from the selected studies focusing on cost-effectiveness results of various vaccination programmes, key contextual and methodological factors influencing cost-effectiveness estimates and an assessment of study quality. RESULTS: A total of 14 studies were included for review. Considerable heterogeneity was found in terms of the methodologies used, HPV vaccination strategies evaluated and study quality. The reviewed studies generally supported the cost-effectiveness of HPV vaccine in China, although some reached alternative conclusions, particularly when assessed incremental to cervical cancer screening. Cost of vaccination was consistently identified as a key determinant for the cost-effectiveness of HPV vaccination programmes. CONCLUSIONS: Implementing HPV vaccination programmes should be complemented with expanded cervical cancer screening, while the release of lower-priced domestic vaccine offers more promising potential for initiating public HPV vaccination programmes. Findings of this study contributes important evidence for policies for cervical cancer prevention in China and methodological implications for future modelling efforts. BMJ Publishing Group 2021-12-08 /pmc/articles/PMC8655525/ /pubmed/34880019 http://dx.doi.org/10.1136/bmjopen-2021-052682 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Health Economics Shi, Wenchuan Cheng, Xiaoli Wang, Haitao Zang, Xiao Chen, Tingting Cost-effectiveness of human papillomavirus vaccine in China: a systematic review of modelling studies |
title | Cost-effectiveness of human papillomavirus vaccine in China: a systematic review of modelling studies |
title_full | Cost-effectiveness of human papillomavirus vaccine in China: a systematic review of modelling studies |
title_fullStr | Cost-effectiveness of human papillomavirus vaccine in China: a systematic review of modelling studies |
title_full_unstemmed | Cost-effectiveness of human papillomavirus vaccine in China: a systematic review of modelling studies |
title_short | Cost-effectiveness of human papillomavirus vaccine in China: a systematic review of modelling studies |
title_sort | cost-effectiveness of human papillomavirus vaccine in china: a systematic review of modelling studies |
topic | Health Economics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8655525/ https://www.ncbi.nlm.nih.gov/pubmed/34880019 http://dx.doi.org/10.1136/bmjopen-2021-052682 |
work_keys_str_mv | AT shiwenchuan costeffectivenessofhumanpapillomavirusvaccineinchinaasystematicreviewofmodellingstudies AT chengxiaoli costeffectivenessofhumanpapillomavirusvaccineinchinaasystematicreviewofmodellingstudies AT wanghaitao costeffectivenessofhumanpapillomavirusvaccineinchinaasystematicreviewofmodellingstudies AT zangxiao costeffectivenessofhumanpapillomavirusvaccineinchinaasystematicreviewofmodellingstudies AT chentingting costeffectivenessofhumanpapillomavirusvaccineinchinaasystematicreviewofmodellingstudies |